Dr. Martens (LON:DOCS) Trading Down 13.2% – Should You Sell?

Dr. Martens plc (LON:DOCS) dropped 13.2% on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 65.65. Approximately 3,540,041 shares changed hands during trading, an increase of 104% from the average daily volume of 1,738,517 shares. The stock had previously closed at GBX 75.65.

Analyst Ratings Changes

Several brokerages have commented on DOCS. Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Price Performance

The firm’s fifty day simple moving average is GBX 75.88 and its 200-day simple moving average is GBX 83.26. The firm has a market capitalization of £657.97 million, a PE ratio of 40.04, a PEG ratio of 6.40 and a beta of 0.11. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS) last announced its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, research analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the stock in a transaction dated Friday, December 5th. The shares were purchased at an average cost of GBX 79 per share, with a total value of £75,840. Insiders acquired a total of 97,130 shares of company stock valued at $7,673,816 in the last three months. 2.79% of the stock is owned by insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.